Castle Biosciences Closes $11.7M Tranche of $20M Series F Financing

Castle-BiosciencesCastle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced it has closed the first tranche of a $20 million Series F financing, raising $11.7 million.

The funding will be used to accelerate the growth in clinical adoption of Castle Biosciences’ gene test for identifying metastatic risk in early stage cutaneous melanoma, DecisionDx-Melanoma, and its other tests designed to improve cancer care.

Victor Hwang of Industry Ventures stated:

Victor Hwang“We are excited to support the continued growth of Castle Biosciences’ clinically important molecular diagnostic tests, building on the commercial success of its uveal melanoma test, and continuing the fast pace of adoption of its cutaneous melanoma test.

 

“We initially invested in Castle Biosciences through a secondary transaction and have been impressed by management’s strategic build-out of its infrastructure, including the recruitment of accomplished executives and board members from the genomics industry, expansion of its sales and marketing efforts, and the continued development and commercialization of important new diagnostic tools for underserved cancers.”

Castle Biosciences’ molecular tests are designed to go beyond traditional staging methods to provide tumor-specific information to help determine the best treatment approach in patients diagnosed with uveal melanoma, cutaneous melanoma, esophageal cancer, mesothelioma and other underserved cancers.

Derek Maetzold, Castle Biosciences President and CEO, explained:

Derek Maetzold“We’re extremely pleased to have Industry Ventures lead this financing round, and to have the continued support of our current investors including HealthQuest Capital and Mountain Group Partners. The funding enables us to expand our efforts to reach physicians and payers, and ultimately increase the number of patients who can benefit from improved cancer staging and better treatment decisions enabled by our molecular diagnostic tests.”

Castle Biosciences anticipates completing the Series F round by the end of the third quarter.


Have a crowdfunding offering you'd like to share? Submit an offering for consideration using our Submit a Tip form and we may share it on our site!

Sponsored Links by DQ Promote

Send this to a friend